Psychotic Disorders - Americas

Americas

Revenue in the Psychotic Disorders market is projected to reach US$3.00bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of -0.50%, resulting in a market volume of US$2.94bn by 2028.
In global comparison, most revenue will be generated in the United States (US$2,257.00m in 2024).
In relation to total population figures, per person revenues of US$233.10 are generated in 2024.

Key regions: Germany, France, United States, Australia, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Psychotic Disorders market in Americas is experiencing significant growth and development due to various factors.

Customer preferences: Customers in the Americas are increasingly seeking effective treatments for psychotic disorders. They are looking for medications that can alleviate symptoms such as hallucinations, delusions, and disorganized thinking. Additionally, there is a growing demand for treatments that have fewer side effects and are more convenient to use. Customers are also interested in therapies that provide long-term management of the disorder and improve their overall quality of life.

Trends in the market: One of the key trends in the Psychotic Disorders market in Americas is the increasing use of antipsychotic medications. These medications are widely prescribed by healthcare professionals to manage psychotic symptoms. There is a growing preference for newer atypical antipsychotics, which have shown to be more effective and have fewer side effects compared to older typical antipsychotics. The market is also witnessing the development of novel therapies, including targeted therapies and gene therapies, which hold promise for more personalized and effective treatment options in the future.

Local special circumstances: The Americas have a significant burden of psychotic disorders, with a high prevalence rate. This has led to increased awareness and focus on the development and availability of treatments for these disorders. The region also has a well-established healthcare infrastructure, including mental health services, which facilitates access to treatment for patients. Additionally, there is a strong research and development ecosystem in the region, with numerous academic institutions and pharmaceutical companies working on innovative therapies for psychotic disorders.

Underlying macroeconomic factors: The growth of the Psychotic Disorders market in Americas is also influenced by several macroeconomic factors. One such factor is the increasing healthcare expenditure in the region. Governments and private payers are allocating more resources to mental health services, including the treatment of psychotic disorders. This has resulted in improved access to healthcare services and medications for patients. Additionally, the region has a large population and a high prevalence of mental health disorders, which creates a significant market opportunity for pharmaceutical companies operating in the region. The presence of a favorable regulatory environment and intellectual property protection also encourages investment in research and development of new therapies for psychotic disorders.In conclusion, the Psychotic Disorders market in Americas is witnessing significant growth and development due to increasing customer preferences for effective treatments, the trend towards the use of antipsychotic medications, local special circumstances such as high prevalence rates and a well-established healthcare infrastructure, and underlying macroeconomic factors such as increased healthcare expenditure and a large market opportunity. These factors are driving innovation and investment in the market, leading to the development of new and improved therapies for psychotic disorders.

Methodology

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.